Search Within

Population Sciences Research Program

  1. "2019"
  2. "Steven Horwitz"
Formats
  1. Meeting Abstract (40)
  2. Journal Article (18)
  3. Editorial (2)
  4. Guidelines (2)
  5. Research Letter (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (64)
  2. Department of Medicine (64)
  3. Hematologic Malignancies, Division of (64)
  4. Lymphoma (64)
  5. Sloan Kettering Institute Postdocs (22)
  6. Survivorship Research (17)

More Groups

People
  1. Steven Horwitz (64)
  2. Alison Moskowitz (27)
  3. Ariela Noy (16)
  4. David Straus (16)
  5. Andrew Zelenetz (15)
  6. Matthew Matasar (15)

More People

Years
  1. 2019 (64)
Publications
  1. Blood (22)
  2. Hematological Oncology (12)
  3. Journal of Clinical Oncology (5)
  4. Blood Advances (2)
  5. European Journal of Cancer (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Wiley Blackwell (16)
  3. American Society of Clinical Oncology (5)
  4. Taylor & Francis Group (3)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL)
    Meeting Abstract

    Sawas, A.; Ma, H.; Shustov, A.; Hsu, P.; Bhat, G.; Acosta, M.; Horwitz, S. M.; O'Connor, O. A.
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A Phase 1/1b dose-escalation trial evaluating CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, in subjects with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Mobasher, M.; Miller, R. A.; Janc, J. W.; Kwei, L.; Buggy, J. J.; Luciano, G.; Mohammady, A.; Kim, W. S.; Kim, Y. H.; Khodadoust, M. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT)
    Meeting Abstract

    Leyfman, Y.; Joffe, E.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Palomba, M. L. L.; Moskowitz, C. H.; Portlock, C. S.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety of mogamulizumab in mycosis fungoides and Sézary syndrome: Final results from the phase 3 MAVORIC study
    Meeting Abstract

    Kim, Y. H.; Bagot, M.; Zinzani, P. L.; Duvic, M.; Morris, S.; Kim, E.; Musiek, A.; Ortiz-Romero, P. L.; Elmets, C.; Eradat, H. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save